Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of PF-04950615 versus placebo in high-risk hyperlipidemia or mixed dyslipidemia
2013-002642-37Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hyperlipidemia and combined dyslipidaemia comparing PF-04950615 plus background statin therapy with Placebo plus background statin therapy (2 arms). Primary endpoint: Percent change from baseline in fasting LDL-C at week 12. Started Nov 2013; status: completed.
02
Drugs
bococizumab
03
Conditions
familial hyperlipidemiacombined dyslipidaemia
Beyond the preview
Go deeper on 2013-002642-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002642-37.